Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.56 |
| ▸ | CKS1B | P61024 | 2/20 | 0.56 |
| ▸ | SKP1 | P63208 | 2/20 | 0.56 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 4/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ADK | P55263 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30480343 | 1.00 | AKR1C3 (0.57) | AKR1C3GPR119CKS1BSKP1SKP2 | |
| SCHEMBL29712339 | 0.99 | AKR1C3 (0.56) | AKR1C3GPR119CKS1BSKP1SKP2 | |
| SCHEMBL594028 | 0.95 | CKS1B (0.59) | AKR1C3GPR119CKS1BSKP1SKP2 | |
| SCHEMBL13100992 | 0.90 | AKR1C3 (0.51) | AKR1C3GPR119CKS1BSKP1SKP2 | |
| SCHEMBL1780700 | 0.89 | RET (0.51) | AKR1C3GPR119CKS1BSKP1SKP2 | |
| SCHEMBL29455974 | 0.89 | RET (0.51) | AKR1C3GPR119CKS1BSKP1SKP2 | |
| SCHEMBL29197774 | 0.87 | AKR1C3 (0.47) | AKR1C3GPR119CKS1BSKP1SKP2 | |
| SCHEMBL30112375 | 0.87 | AKR1C3 (0.47) | AKR1C3GPR119CKS1BSKP1SKP2 | |
| SCHEMBL1753703 | 0.86 | RET (0.51) | GPR119DDB1CRBNRETHPGD | |
| SCHEMBL30392218 | 0.86 | RET (0.51) | AKR1C3GPR119DDB1CRBNRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| US-12479853-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3909949-B1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| WO-2025128805-A1 | A CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025108106-A1 | COMPOUND CONTAINING QUINOLINONE SKELETON AND USE THEREOF | 中国药科大学 | 2025-05-30 | — | — | WO | disclosed |
| CN-120040416-A | Piperazine amide skeleton compound and application thereof | 中国药科大学 | 2025-05-27 | — | — | CN | disclosed |
| EP-1282614-B1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-11-12 | — | — | EP | disclosed |
| US-6552029-B1 | For therapy of rheumatoid arthritis, psoriasis, graft v. host disease, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, complications following percutaneous transluminal coronary angioplasty, thrombosis | CELLTECH R&D LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |
| EP-0934304-B1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| EP-1282614-A1 | HYDROXAMIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2003-02-12 | — | — | EP | disclosed |
| US-20020037900-A1 | Hydroxamic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-03-28 | — | — | US | disclosed |
| WO-2001087870-A1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
| US-6114333-A | 2-Pyrimidineamine derivatives and processes for their preparation | CELLTECH THERAPEUTICS LTD. (GB) | 2000-09-05 | — | — | US | disclosed |
| US-6093716-A | Substituted 2-pyrimidineamines and processes for their preparation | CELLTECH THERAPEUTICS, LIMITED (GB) | 2000-07-25 | — | — | US | disclosed |
| EP-0934304-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998018782-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HRH3, HRH4, HRH2 | AKR1C3 425/4885GPR119 1257/4885CKS1B 2601/4885 |
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | PARP1, PARP11, PARP12 | AKR1C3 3460/4885GPR119 1130/4885CKS1B 380/4885 |
| US-12479853-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | AKR1C3 318/4885GPR119 2624/4885CKS1B 584/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | AKR1C3 930/4885GPR119 866/4885CKS1B 1183/4885 |
| US-20020037900-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | AKR1C3 1673/4885GPR119 4313/4885CKS1B 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.